Abstract
✓ Bis-chlorethyl-nitrosourea (BCNU) is one of the numerous experimental chemotherapeutic agents used to treat recurrent brain tumors. The clinical response and the angiographic changes in tumor vascularity were compared in 32 patients treated with BCNU for recurrent primary brain tumor. In five of 22 initially vascular lesions the tumor vasculature increased, in 11 it decreased, and in six it remained unchanged after treatment. There was no correlation between angiographic changes in the tumor and the clinical course following BCNU therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
